This content is protected against AI scraping.
The White House is holding four meetings this week with cannabis industry leaders and researchers to discuss a pending FDA enforcement policy for CBD products. These sessions aim to shape upcoming federal guidance on how CBD is regulated and policed, particularly as the industry prepares for significant legal changes and a new ban on many THC-infused consumables taking effect in November.
Simultaneously, the Centers for Medicare & Medicaid Services (CMS) is launching a pilot program that could cover up to $500 annually for hemp-derived CBD products. To qualify for coverage, products must meet strict safety standards, including being an oral solution with no more than 0.3% delta-9 THC.
Since the FDA has already missed key deadlines for providing a clear list of approved cannabinoids, stakeholders are left hopeful that these White House meetings will finally provide the clarity the industry needs. This is a summary. Read the original article.
Original article written by Kyle Jaeger. Published on March 30, 2026 by Marijuana Moment.
